NEW YORK (GenomeWeb) – MDNA Life Sciences announced today that it has signed an agreement making BL&H the exclusive South Korean distributor of its PCR-based liquid biopsy prostate cancer test, the Prostate Mitomic Test (PMT).
PMT analyzes the mitochondrial genome to determine which men with clinical suspicion of prostate cancer are likely to have high-grade disease that may require immediate intervention. The test's negative predictive value can also help identify cases that can safely delay or forego immediate biopsy.
"BL&H has extensive regulatory experience and has strong relationships with key hospital centers in South Korea," MDNA President and CEO Chris Mitton said in a statement. "We look forward to building on this relationship by licensing additional Mitomic diagnostic tests to BL&H as they become available."
In addition to PMT, MDNA sells a post-biopsy tissue-based prostate cancer test, and is developing a liquid biopsy test for endometriosis in collaboration with the University of Oxford.
In recent months, the company has inked deals with Helomics and Phi Life Sciences to distribute PMT in the US. MDNA said that it intends to find additional international partners for its liquid biopsy tests.